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About chemodectomas
occurring concurrently in two
sites: In the mediastinum
and the lungs
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Case  report
The  patient  is  a  48-year-old  female  patient  with  an  unre-
markable  medical  history  who  underwent  a  lung  X-ray  for
bronchitis.  The  lung  X-ray  showed  overhanging  of  the  medi-
astinal  left  aortic  arch  suggestive  of  a  mediastinal  mass.
A  chest  CT  scan  was  carried  out  with  a  slice  thickness  of
0.75  mm  and  mediastinal  and  parenchymal  window  settings,
with  and  without  contrast  injection  for  enhancement  of  the
arterial  and  venous  phases.  The  CT  scan  showed  two  well-
delimited  masses  with  regular  contours,  one  located  in  the
anterosuperior  mediastinum  measuring  35  ×  27  mm  (Fig.  1)
and  the  other  in  the  apical  segment  of  the  parenchyma
measuring  15  mm  (Fig.  2).  The  two  tumours  showed  intense
enhancement  early  after  contrast  injection,  otherwise  no
mediastinal  adenomegaly  or  other  thoracic  lesions  were
observed.
The  conclusion  after  the  scan  was  that  the  tumour  was  a
hypervascular  tumour  with  a  double  location  (mediastinum
Figure 1. Small, well-delimited, homogeneous anterosuperior
mediastinal mass enhanced following contrast injection, in front of
the aortic arch and behind the sternum with no lytic bony lesions.
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2211-5684/© 2014 Published by Elsevier Masson SAS on behalf of the Édind  lung)  and  the  ﬁrst  hypotheses  pointed  to  the  diagnosis:
 paraganglioma,  a  carcinoid  tumour  or  a  thymoma.  . .
Histopathological  examination  of  samples  obtained  by
T-guided  biopsy  of  the  anterior  mediastinal  mass  conﬁrmed
he  diagnosis  of  a  benign,  non-secretory  chemodectoma-
ype  paraganglioma.
Monitoring  was  indicated  for  the  patient  in  the  absence
f  a  compressive  syndrome  or  symptoms  of  heart  disease  or
ypertension.
iscussion
aragangliomas  are  tumours  that  develop  from  the  adrenal
edulla  (pheochromocytomas)  or  in  the  extra-adrenal  para-
anglia.  Only  extra-adrenal  paraganglia  will  be  discussed  in
his  article.  Paraganglionic  tissue  (neuroendocrine  system)
s  made  up  of  cells  deriving  from  the  neural  crest  and  may
e  divided  into  two  groups.
Paraganglionic  tissue  from  the  ﬁrst  group  is  distributed
long  the  length  of  the  pre-  and  para-vertebral  sympa-
hetic  chain  and  the  sympathetic  nervous  system  innervating
he  pelvic  and  retroperitoneal  organs  (orthosympathetic
ystem:  retroperitoneal  chromafﬁn  cells  including  the
rgan  of  Zuckerkandl)  and  gives  rise  to  retroperitoneal
aragangliomas,  mediastinal  paragangliomas,  spinal  para-
angliomas,  ﬁlum  terminale,  cauda  equine,  paragangliomas
f  the  kidneys,  bladder,  endometrium,  vulva,  heart  and
ungs  [1—3].
Paraganglionic  tissue  from  the  second  group, distributed
long  the  length  of  the  parasympathetic  nervous  system
nd  concerning  mostly  the  cervical  and  thoracic  branches  of
he  glossopharyngeal  and  pneumogastric  nerves  (parasym-
athetic  system:  nonchromafﬁn  cells  with  a  chemoreceptor
unction:  head,  neck,  mediastinum),  gives  rise  to  paragan-
liomas  of  the  head  and  neck  (chemodectomas):  carotid
aragangliomas,  jugular-tympanic  paragangliomas,  vagal
aragangliomas,  paragangliomas  of  the  orbits,  the  nasal
ossa,  the  nasopharynx,  the  trachea,  the  thyroid  and  the
arynx.  They  are  never  located  on  the  limbs  [1—3].
Paragangliomas  are  mostly  sporadic,  single  tumours,
ccurring  in  subjects  between  40  and  60  years  of  age.
owever,  the  tumours  may  develop  at  multiple  sites  and
amilial  forms  also  exist  but  in  such  cases,  the  patients
re  younger.  They  are  sometimes  combined  with  a multiple
ndocrine  neoplasia  syndrome.  Paragangliomas  are  discon-
inuous  aggregates  of  neural  crest  cells.  They  are  found  in
he  adrenal  medulla,  along  the  aorta,  in  blood  vessel  walls
tions françaises de radiologie.
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pigure 2. Small lung tissue lesion with the same characteristics a
indow (a) and parenchymal window (b) showing its perivascular lo
nd  in  certain  organs  such  as  the  heart,  the  prostate  or
he  ovaries.  Paragangliomas  develop  at  the  cost  of  paragan-
lionic  structures.  Tumours  that  develop  from  sympathetic
tructures  are  most  often  active  and  are  referred  to  as
heochromocytomas  in  the  adrenal  glands  and  active  para-
angliomas  when  they  develop  outside  the  adrenal  glands.
umours  that  develop  from  parasympathetic  structures  are
ostly  inactive  and  referred  to  as  chemodectomas  or  inac-
ive  paragangliomas.  Thoracic  paragangliomas  account  for
ess  than  2%  of  mainly  adrenal  paragangliomas  [4]  and  their
oncurrent  occurrence  in  two  sites  is  exceptional.
Macroscopically,  chemodectomas  are  soft  and  richly
ascularised  tumours.  Histologically,  the  cells  are  oval,  sep-
rated  by  reticulin  ﬁbres  and  show  no  mitotic  activity.
owever,  distinguishing  chemodectomas  from  pheochro-
ocytomas  may  be  tricky  [4].  Currently,  the  distinction
etween  secretory  and  non-secretory  tumours  is  based  on
aboratory  ﬁndings  and  not  on  histopathological  examina-
ion  alone.  Only  10%  of  pheochromocytomas,  but  20%  of  the
xtra-adrenal  forms,  are  malignant.  Malignancy  is  based  on
he  presence  of  metastases.
Paragangliomas  occur  most  frequently  in  adults  between
0  and  40  years  of  age.  Chemodectomas  may  also  present
s  a  mass  leading  to  the  compression  of  an  intercostal
erve,  the  spinal  cord,  Claude  Bernard-Horner  syndrome
5]  and  even  symptoms  of  heart  disease  due  to  compres-
ion  of  the  coronary  artery  or  atrium  [6].  The  symptoms
f  pheochromocytomas  are  mainly  related  to  their  secre-
ion  of  catecholamines  giving  rise  to  hypertension,  stroke,
enal  or  cardiac  insufﬁciency,  weight  loss,  diabetes,  etc.
ore  atypical  symptoms  such  as  tachycardia,  anxiety,  palpi-
ations,  nausea,  vomiting  or  headache  may  also  be  observed.
aragangliomas  may  sometimes  secrete  other  hormones,
iving  rise  to  Cushing’s  syndrome  (secretion  of  ACTH),  poly-
ythemia  (secretion  of  EPO),  hyperkalcemia  (secretion  of
TH)  and  diarrhoea  (secretion  of  VIP).
Malignant  paragangliomas  may  be  immediately
etastatic  with  a  frequency  estimated  at  20%.  Bone
etastases  are  the  most  common  metastases.  Other  sites
f  metastasis  include  regional  lymph  nodes,  the  lung  and  the
iver.  Skin  and  brain  metastases  have  been  reported  more
arely  [4].  In  close  to  10%  of  cases,  pheochromocytomas
re  associated  with  multiple  endocrine  neoplasias  (MEN  IIa
nd  IIb),  Von  Hippel-Lindau  disease  or  neuroﬁbromatosis
4].  In  some  cases,  several  paraganglionic  tumours  may  be
p
l
dment 6 of the inferior lobe of the left lung; axial slice, mediastinal
n.
bserved  concurrently  which  should  call  to  mind  the  Carney
riad  (coexistence  of  multiple  extra-adrenal  pheochro-
ocytomas,  lung  hamartomas  and  gastric  gastrointestinal
tromal  tumours)  [7].
Imaging  techniques  are  used  to  precisely  locate  the
umour  and  determine  the  extent  to  which  it  has  spread.
he  concurrent  occurrence  of  chemodectomas  in  two  sites
as  rarely  been  described.  Paragangliomas  may  be  observed
n  the  cardiac  ﬁeld  and  in  the  pulmonary  grooves  [8].  A  chest
-ray  may  show  enlargement  of  the  superior  mediastinum,
 change  in  the  cardiac  silhouette  or  lung  metastases.
A  CT  scan  without  and  then  with  contrast  injection  can
e  used  to  better  visualise  the  lesion  and  speciﬁcally  ana-
yse  the  tumour  by  deﬁning  its  morphological  characteristics
nd  its  topography.  The  tumour  is  generally  a homogeneous,
ell-delimited  tissue  mass  isodense  to  muscles  showing
ntense  enhancement  after  contrast  injection.  CT  scans  also
nable  the  study  of  the  tumour  with  respect  to  different
rgans  as  well  as  tumour  extension.  However,  due  to  the
roximity  of  the  heart  and  large  blood  vessels,  cardiac  gat-
ng  may  be  required  for  small  tumours  not  to  be  missed.
ith  MRI,  the  tumour  is  isointense  to  muscles,  hyperin-
ense  on  T2-weighted  images  with  a  serpiginous  appearance
ndicative  of  vascular  involvement.  The  salt  and  pepper
ppearance  due  to  the  juxtaposition  of  hypersignals  and
yposignals  is  not  always  seen,  but  contrast  uptake  is  con-
istently  massive.
Diagnostic  arteriography  is  an  optional  test  used  to
isualise  the  tumour  blush  characteristic  of  hypervascular
umours  and  to  map  blood  ﬂow.  A  further  advantage  of  the
est  is  that  it  can  be  used  for  pre-surgical  embolization  to
educe  preoperative  bleeding  and  the  volume  of  the  tumour.
The  sensitivity  and  speciﬁcity  of  MIBG  scintigraphy  is
espectively  70%  and  98%  for  the  diagnosis  of  paragangliomas
9],  irrespective  of  whether  they  are  secretory  or  not.  Possi-
le  alternatives  include  somatostatin  analogue  scintigraphy
OctreoScan)  that  displays  a  sensitivity  of  22%  [10],  or  PET
ith  6-(18)F-ﬂuorodopamine,  found  to  be  the  most  sensitive
echnique  (90%)  in  a  recent  study  [10].  Nonetheless,  Octre-
Scans  are  still  useful  in  cases  of  metastatic  or  extra-adrenal
aragangliomas.
Tumour  appearance  with  medical  imaging  is  not  speciﬁc,
articularly  when  the  tumours  occur  in  unusual  locations
ike  in  this  case.  Consequently,  it  is  important  to  make  a
iagnosis  so  anaesthetic  accidents  may  be  avoided  during
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surgery  and  to  implement  special  procedures  for  general
anaesthesia.
Localised  paragangliomas  are  treated  surgically.  Prior  to
surgery,  patients  may  require  embolization  because  non-
secretory  tumours  are  often  richly  vascularised.  Surgery
is  performed  using  a  direct  approach  by  sternotomy  or
thoracotomy  depending  on  where  the  tumour  is  located.
Extracorporeal  circulation  may  be  required  for  the  removal
of  inﬁltrating  tumours  [5].  Complete  tumour  resection  is
curative  in  cases  of  localised  tumours  [5].  In  cases  of  malig-
nant  disseminated  tumours,  chemotherapy  or  Iodine-131
MIBG  scintigraphy  only  helps  to  stabilise  the  disease  and
progression  generally  occurs  within  2  years.
Conclusion
Chemodectomas  are  tumours  of  the  extra-adrenal  para-
ganglionic  system  located  along  the  length  of  the
cervical-cranial  parasympathetic  nervous  system.  Tumour
occurrence  in  the  mediastinal  area  is  rare  and  a  double
mediastinal  and  lung  location  is  even  rarer.  CT  scans  and
MRI  are  essential  for  making  a  diagnosis  and  studying  the
tumour  with  respect  to  the  other  organs  but  the  information
acquired  by  these  imaging  techniques  is  unspeciﬁc,  particu-
larly  when  the  tumours  occur  in  unusual  locations  such  as  in
this  case.  Consequently,  it  is  important  to  make  a  diagnosis
so  anaesthetic  accidents  may  be  avoided  during  surgery  and
to  implement  special  procedures  for  general  anaesthesia.
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